What Is an STI Test and What Does It Check For?

An STI test is any laboratory procedure used to detect a sexually transmitted infection, and what it checks for depends on the specific panel your provider orders or you request. There is no single “full STI test” that covers everything in one go. Most standard screens target chlamydia, gonorrhea, syphilis, HIV, and sometimes hepatitis B and C, but several common infections like herpes, trichomoniasis, HPV, and Mycoplasma genitalium require separate tests that are not always included unless you ask. The method behind each test also varies: some look for the pathogen’s genetic material, some detect antibodies your immune system has produced, and some rely on a direct sample from a sore or lesion.

What a Typical STI Panel Includes

When a clinic or provider offers “STI testing,” they usually mean a core set of infections that public health guidelines prioritize. In the United States, the CDC’s 2021 treatment guidelines emphasize screening for chlamydia, gonorrhea, and syphilis, noting that annual reported cases of these three infections alone exceeded an estimated 2.5 million in 2019, with congenital syphilis rising sharply over the preceding years.¹ HIV testing is generally bundled in. Many clinics also include hepatitis B and hepatitis C serology, particularly for people with risk factors, following European and American guidelines that recommend screening in sexual health settings.²

Beyond that core set, trichomoniasis, herpes (HSV-1 and HSV-2), HPV, and Mycoplasma genitalium are tested for selectively, not routinely. This matters because many people walk out of a clinic believing they have been tested for “everything” when they have only been screened for a handful of infections. If you have specific concerns or symptoms, ask your provider exactly which pathogens the panel covers.

How the Tests Actually Work

The underlying technology depends on what the test is looking for. Most chlamydia and gonorrhea screening now uses nucleic acid amplification testing, often called NAAT. This method detects tiny amounts of a pathogen’s DNA or RNA in a urine sample or swab, and it is the gold standard for these two infections because of its high sensitivity. PCR-based testing on a first-void urine sample, for instance, offers the advantage of being non-invasive and self-collectable while maintaining high sensitivity and specificity.³

For HIV, syphilis, and hepatitis, the approach is different. These tests typically rely on blood draws or finger-prick samples that look for antibodies your body has made in response to infection, or in some cases antigens (pieces of the pathogen itself). Rapid point-of-care tests using immunochromatographic strips now exist for HIV, hepatitis C, and syphilis, making supervised self-testing feasible and accurate for these infections.⁴ Herpes, by contrast, is usually tested either by swabbing an active sore for PCR analysis or through a type-specific blood test that detects antibodies to HSV-1 or HSV-2.

Multiplex PCR panels represent a newer development. These run a single sample against primers for many pathogens at once. One such system tested concordance rates of 98% for chlamydia and 97% for gonorrhea compared to standard NAAT, while also screening for syphilis, trichomoniasis, Mycoplasma genitalium, herpes types 1 and 2, and other organisms in a single automated run.⁵ Another validated real-time PCR panel achieved near-perfect sensitivity and specificity across nine STI targets simultaneously.⁶ These multi-pathogen panels are not yet the norm in most clinics, but they are becoming more available and could eventually replace ordering separate tests for each infection.

Specimen Types and Self-Collection

What you provide as a sample depends on the infection being tested and your anatomy. For chlamydia and gonorrhea in women, the CDC recommends vaginal swabs as the optimal specimen type, and these can be self-collected. A meta-analysis comparing vaginal swabs to urine found pooled sensitivity of about 94% versus 87% for chlamydia and roughly 97% versus 91% for gonorrhea, meaning vaginal swabs catch more infections.⁷ For men, urine is the standard specimen for chlamydia and gonorrhea screening from the genital site, with sensitivity above 90% for both infections when compared to clinician-collected urethral swabs.⁸

A key practical point: self-collected specimens perform about as well as those collected by a healthcare worker. An updated systematic review and meta-analysis found that self-collected specimens demonstrated comparable diagnostic accuracy across most STIs, suggesting that self-collection can provide reliable results and make testing more accessible.⁹ This finding is what underpins the growing availability of at-home test kits and self-swab options at clinics, where a provider hands you the materials and you collect the sample yourself in a restroom.

Why Testing Site on the Body Matters

If you only provide a urine sample or a genital swab, you may be missing infections entirely. Chlamydia and gonorrhea can live in the throat and rectum, and for men who have sex with men, the majority of infections are found at these extragenital sites rather than the genitals. Research reviewing cases in one city found that 70% of gonorrhea infections and 65% of chlamydia infections were exclusively extragenital, meaning they would have been completely missed by genital-only testing.¹⁰ A study in Bulgaria painted a similar picture: more than 80% of extragenital infections would have gone undetected if only symptomatic cases were investigated, because most people with rectal or throat infections have no symptoms at all.¹¹

The practical takeaway: if you have had oral or anal sex, tell your provider, because a standard urine-only test will not catch infections at those sites. Many clinics now offer self-collected throat and rectal swabs for NAAT testing, and studies confirm these self-swabs are as reliable as those collected by clinicians.¹⁰

Window Periods and When to Test

Every STI test has a window period, which is the gap between when you acquire an infection and when the test can reliably detect it. Testing too soon after exposure often produces a negative result even if you are infected, because the pathogen or your immune response has not built up enough to register.

For HIV, the window period depends heavily on the test generation. Fourth-generation rapid tests that detect both antibodies and a viral protein called p24 antigen have substantially shortened the wait. One study comparing rapid test formats found that a fourth-generation test reached about 78% sensitivity between two and three weeks after infection and about 90% sensitivity from three weeks to one month, whereas an older antibody-only test was still producing negative results as late as 70 to 90 days after infection.¹² Standard lab-based fourth-generation tests are even more sensitive than rapid versions and can often detect infection within two to four weeks. RNA-based tests (sometimes called viral load tests) detect the virus itself and have been explored as a way to further shorten the window in post-exposure settings.¹³

For chlamydia and gonorrhea detected by NAAT, the window is shorter, typically around one to two weeks after exposure. Syphilis antibody tests may not turn positive for several weeks after a chancre appears. A general rule: if you had a specific exposure and test negative within the first week or two, consider retesting after the appropriate window for the infection you are most concerned about. Your provider can advise on timing.

How Syphilis Testing Works

Syphilis screening deserves its own explanation because it uses a two-step process unlike chlamydia or gonorrhea testing. Two different families of blood tests exist: nontreponemal tests (like RPR or VDRL) that detect general markers of tissue damage, and treponemal tests (like TPHA or FTA-Abs) that detect antibodies specific to the syphilis bacterium. A positive result from one type needs to be confirmed by the other.¹⁴

In the traditional approach, the nontreponemal test is run first, and reactive samples are confirmed with a treponemal test. Many labs now use a “reverse algorithm,” starting with a treponemal test and following up positive results with a nontreponemal test. When those two disagree, a second treponemal test is used to resolve the discrepancy.¹⁵ This layered process exists because no single test is perfectly reliable for syphilis. Nontreponemal tests can produce false positives in people with certain autoimmune conditions or recent viral infections, and treponemal tests stay positive for life after infection, even after successful treatment. So interpreting syphilis results often requires a provider who understands which algorithm was used and what the combination of results means.

Herpes Testing Is Less Straightforward Than You Might Expect

Herpes simplex virus occupies an unusual spot in STI testing because routine screening is not recommended for people without symptoms. If you have an active sore, PCR testing on a swab from the lesion is the most sensitive method and is increasingly replacing older viral culture techniques as the preferred approach.¹⁶ PCR catches more infections than culture, regardless of the sore’s location or whether HSV-1 or HSV-2 is responsible.

For people without symptoms who want to know their status, a type-specific blood test based on glycoprotein G can distinguish between HSV-1 and HSV-2 antibodies. However, this blood test has meaningful limitations. False positives occur, especially at low index values, and a positive HSV-1 result does not tell you whether the infection is oral or genital. Most guidelines discourage widespread antibody screening in people without symptoms because the results often cause more anxiety than they resolve, and the false-positive rate in low-risk populations makes interpretation difficult.

HPV Screening Is Its Own Category

Human papillomavirus testing works differently from the infections above. HPV is not part of a standard STI panel. Instead, it is used as a cervical cancer screening tool, usually alongside or in place of a Pap smear. The HPV test detects high-risk viral strains that can cause cervical cell changes and, eventually, cancer.

How HPV DNA testing compares to traditional Pap smears depends on what you are trying to detect. A large randomized trial found that HPV testing had a sensitivity of about 95% for detecting precancerous cervical lesions, compared to about 55% for Pap testing, though Pap had slightly higher specificity.¹⁷ A meta-analysis of randomized trials confirmed that HPV DNA testing detects more high-grade lesions than cytology, and that in women aged 30 and older, the specificity of the two tests was similar, making HPV testing a strong primary screening option for that age group.¹⁸ For younger women, HPV testing catches more transient infections that will clear on their own, which can lead to unnecessary follow-up procedures. That is why most guidelines reserve primary HPV screening for women over 25 or 30, depending on the country.

One institutional retrospective found that Pap smears actually outperformed HPV tests for detecting the highest-grade lesions and squamous cell carcinoma, with sensitivity of about 97% versus 88% for HPV testing at that threshold.¹⁹ This is why many screening programs use co-testing, running both an HPV test and a Pap together, rather than relying on either one alone.

False Positives in Low-Risk Populations

No test is perfect, and even highly accurate tests can produce misleading results when the infection being tested for is rare in the population being screened. This is a statistical reality that catches many patients off guard. In a military healthcare setting where gonorrhea prevalence was low (about 1% of tests came back positive), the calculated positive predictive value of a nucleic acid amplification test was only 60%, meaning about four out of every ten positive results were false.²⁰²¹

This does not mean the tests are unreliable. In higher-prevalence settings, like an STI clinic where many patients actually have the infection, the same test performs much more predictably. The lesson for you: if you receive a positive gonorrhea result and you are in a demographic or behavioral group where gonorrhea is uncommon, it is reasonable to ask for a confirmatory test before starting treatment. Providers working in low-prevalence populations are increasingly aware of this issue.

Mycoplasma genitalium and Newer Targets

Mycoplasma genitalium (often abbreviated MG) is a bacterium that causes urethritis in men and cervicitis and pelvic inflammatory disease in women, yet it was not even routinely testable until recently. Validated molecular tests now exist with sensitivity above 99% for detecting MG using transcription-mediated amplification.²² The challenge with MG is not just finding it but treating it: resistance to the first-line antibiotic azithromycin was found in roughly 40% of positive samples in studies from Scandinavia and the Netherlands, and resistance to the backup drug moxifloxacin was present in about 6 to 8% of cases.²³ Some newer multiplex panels now include MG alongside chlamydia and gonorrhea, and resistance testing can be performed simultaneously on positive samples to guide antibiotic choice.

Trichomoniasis, caused by the parasite Trichomonas vaginalis, is another infection frequently left off standard panels despite being one of the most common curable STIs worldwide. NAAT testing is the most sensitive option, though older methods like wet-mount microscopy (looking at a sample under the microscope during the visit) are still used in some clinics. Wet mounts miss a substantial fraction of infections, so if trichomoniasis is a concern, specifically requesting a NAAT-based test is worthwhile.

Direct-to-Consumer and At-Home Test Kits

The rise of companies offering mail-order STI test kits has made it possible to get screened without visiting a clinic. You typically order online, receive a kit with instructions for collecting urine, blood via finger prick, or swabs, and send it back to a lab for analysis. The American Sexually Transmitted Diseases Association has acknowledged the potential of these services to expand screening access, while raising concerns about whether appropriate tests are being ordered, whether results are communicated clearly, and whether people who test positive are connected to treatment.²⁴

The accuracy of self-collected samples is generally comparable to clinician-collected ones, as covered earlier, so the lab science behind these kits is sound. The gaps tend to be in what happens after the result. A clinic visit includes a conversation with a provider who takes a sexual history, decides which infections to test for based on your risk profile, explains results in context, prescribes treatment on the spot, and discusses partner notification. A DTC service may handle some of those steps through telehealth consultations, but the handoff is often less seamless. If you go the at-home route, check whether the service includes a provider consultation, whether extragenital testing is available (many kits only offer urine or genital swabs), and what happens if you test positive.

Sample Handling and Practical Logistics

One concern with at-home kits and self-collection is whether the sample degrades before it reaches the lab. Research evaluating storage conditions for gonorrhea NAAT found that analytical sensitivity held up well from two days out to thirty days after collection and across temperatures ranging from frozen to body temperature, though performance varied depending on the transport medium used. Commercial transport buffers designed for NAAT testing maintained higher sensitivity than generic alternatives, especially at warmer temperatures.²⁵ In practical terms, this means following the kit’s instructions on which tube or medium to use matters more than rushing your sample to the mailbox within hours. But leaving a sample in a hot car for days before mailing it could reduce accuracy.

For clinic-based testing, logistics are simpler. NAAT urine specimens are collected as a “first-void” sample, meaning the first part of the urine stream rather than midstream. This is the opposite of what you may have been told for a urinary tract infection test. The first-void approach captures more of the pathogen material that has accumulated in the urethra. Eating, drinking, or urinating shortly before providing a sample can dilute it, so many clinics recommend not urinating for at least an hour before testing.

Why There Is No Single “Complete” STI Test

The reason no single test covers all STIs comes down to biology. Different pathogens live in different body sites, shed in different ways, and trigger different immune responses. A urine NAAT excels at finding chlamydia and gonorrhea DNA in the genital tract but tells you nothing about your HIV or syphilis status, which require blood-based antibody detection. A blood draw for syphilis and HIV does not detect chlamydia or gonorrhea. Herpes only reliably shows up on a swab when a sore is present, and blood testing for it is complicated by false-positive concerns. HPV testing is tied to cervical screening and is not routinely performed on men at all, because there is no approved HPV test for the male genital tract, throat, or rectum outside of research settings.

Point-of-care tests exist for syphilis and HIV that can give results in minutes from a finger prick, but equivalent rapid tests for chlamydia, gonorrhea, and trichomoniasis are fewer and generally less accurate than lab-based NAAT.²⁶ The technology is advancing, but for now, thorough screening typically means a combination of specimens: a urine sample or swab for bacterial and parasitic infections, a blood draw for HIV, syphilis, and hepatitis, and site-specific swabs if you have had oral or anal exposure. Knowing what is and is not included in your test panel is the single most useful thing you can do to make sure you are actually getting the screening you need.